AR080331A2 - Proteina nef-tat-his o nef-mutada tat-his, metodo para prepararla y metodo para producir una vacuna que comprende dicha proteina - Google Patents

Proteina nef-tat-his o nef-mutada tat-his, metodo para prepararla y metodo para producir una vacuna que comprende dicha proteina

Info

Publication number
AR080331A2
AR080331A2 ARP110100606A ARP110100606A AR080331A2 AR 080331 A2 AR080331 A2 AR 080331A2 AR P110100606 A ARP110100606 A AR P110100606A AR P110100606 A ARP110100606 A AR P110100606A AR 080331 A2 AR080331 A2 AR 080331A2
Authority
AR
Argentina
Prior art keywords
protein
nef
tat
derivative
hiv
Prior art date
Application number
ARP110100606A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10819735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080331(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of AR080331A2 publication Critical patent/AR080331A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A) una proteína Tat de VIH o un derivado de ella, enlazada o bien (i) a un partícipe en la fusion o (ii) a una proteína Net de VIH o un derivado de ella; o (b) a una proteína Net de VIH o un derivado de ella, enlazada o bien (i) a un partícipe en la fusion o (ii) a una proteína Tat de VIH o un derivado de ella; o (c) a una proteína Nef de VIH o un derivado de ella, enlazada a una proteína Tat de VIH o un derivado de ella, y un participe en la fusion. Además un ácido nucleico que codifica dicha proteína y una célula hospedante, tal como Pichia pastoris, transformada con el ácido nucleico antes mencionado.
ARP110100606A 1997-09-26 2011-02-28 Proteina nef-tat-his o nef-mutada tat-his, metodo para prepararla y metodo para producir una vacuna que comprende dicha proteina AR080331A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9720585.0A GB9720585D0 (en) 1997-09-26 1997-09-26 Vaccine

Publications (1)

Publication Number Publication Date
AR080331A2 true AR080331A2 (es) 2012-03-28

Family

ID=10819735

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980104779A AR017147A1 (es) 1997-09-26 1998-09-24 Composicion de vacuna de proteina que comprende una proteina nef de vih, dicha proteina, metodo para prepararla y metodo para producir dicha vacuna
ARP110100606A AR080331A2 (es) 1997-09-26 2011-02-28 Proteina nef-tat-his o nef-mutada tat-his, metodo para prepararla y metodo para producir una vacuna que comprende dicha proteina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980104779A AR017147A1 (es) 1997-09-26 1998-09-24 Composicion de vacuna de proteina que comprende una proteina nef de vih, dicha proteina, metodo para prepararla y metodo para producir dicha vacuna

Country Status (27)

Country Link
EP (1) EP1015596B2 (es)
JP (2) JP2001518300A (es)
KR (1) KR100554487B1 (es)
CN (1) CN1188519C (es)
AR (2) AR017147A1 (es)
AT (1) ATE338128T1 (es)
AU (1) AU746564B2 (es)
BR (1) BR9812547A (es)
CA (1) CA2305013C (es)
CO (1) CO4810339A1 (es)
CZ (1) CZ302878B6 (es)
DE (1) DE69835756T3 (es)
DK (1) DK1015596T4 (es)
ES (1) ES2272012T5 (es)
GB (1) GB9720585D0 (es)
HU (1) HUP0004896A3 (es)
IL (1) IL135102A0 (es)
NO (2) NO328824B1 (es)
NZ (1) NZ503482A (es)
PL (1) PL195243B1 (es)
PT (1) PT1015596E (es)
SA (1) SA98190877B1 (es)
SI (1) SI1015596T2 (es)
TR (1) TR200000864T2 (es)
TW (1) TW499436B (es)
WO (1) WO1999016884A1 (es)
ZA (1) ZA988789B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
AU3158900A (en) * 1999-02-25 2000-09-14 Smithkline Beecham Biologicals (Sa) Immunogens comprising a peptide and a carrier derived from h.influenzae protein
WO2000061617A2 (en) * 1999-04-12 2000-10-19 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
WO2001000232A2 (en) * 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
OA12168A (en) * 2000-01-31 2006-05-08 Smithkline Beecham Biolog Vaccine for the prophylactic or therapeutic immunization against HIV.
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
KR100466382B1 (ko) * 2002-01-08 2005-01-14 주식회사 엘지생명과학 인간 면역 결핍 바이러스-1, -2 타입의 단백질이 융합된 재조합 콤보 단백질, 이의 생산방법, 이를 포함하는 벡터, 형질전환된 대장균 및 진단키트
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
KR20100063126A (ko) * 2002-05-16 2010-06-10 버베리안 노딕 에이/에스 Ｈｉｖ 조절/부속 단백질의 융합 단백질
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
WO2005090968A1 (en) 2004-03-16 2005-09-29 Inist Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0507003D0 (en) * 2005-04-06 2005-05-11 Molmed Spa Therapeutic
IN2014DN06624A (es) 2005-10-18 2015-07-10 Univ Colorado
KR101761691B1 (ko) 2007-11-28 2017-07-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
WO2009105084A2 (en) 2007-11-28 2009-08-27 The Trustees Of The University Of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
EP2250255A2 (en) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
CA2731767C (en) 2008-07-21 2016-12-06 Taiga Biotechnologies, Inc. Differentiated anucleated cells and method for preparing the same
DK2966084T3 (en) 2008-08-28 2018-08-06 Taiga Biotechnologies Inc MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC
US8940290B2 (en) 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
AU2010230073B2 (en) 2009-03-23 2016-05-26 Pin Pharma, Inc. Treatment of cancer with immunostimulatory HIV Tat derivative polypeptides
WO2010138675A1 (en) 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
EP2708561A4 (en) * 2011-03-15 2014-09-24 Univ Yonsei Iacf BIO-PIN
SG10201609511XA (en) 2012-05-18 2016-12-29 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
WO2014012090A1 (en) 2012-07-13 2014-01-16 The Broad Institute, Inc. Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof
AU2013292330B2 (en) 2012-07-20 2018-07-12 Htyr Acquisition Llc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
EP3052127A1 (en) 2013-10-04 2016-08-10 PIN Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
MY186389A (en) 2014-05-13 2021-07-22 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof
US10272160B2 (en) * 2015-04-16 2019-04-30 The Research Foundation For The State University Of New York Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
US11207421B2 (en) 2015-04-16 2021-12-28 The Research Foundation For The State University Of New York Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
CN113786476A (zh) 2016-12-02 2021-12-14 泰加生物工艺学公司 纳米颗粒调配物
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
JP2022532608A (ja) 2019-05-14 2022-07-15 タイガ バイオテクノロジーズ，インク． Ｔ細胞疲弊を処置するための組成物および方法
CA3173793A1 (en) 2020-04-03 2021-10-07 Andrew Ferguson Infectious disease antigens and vaccines
WO2022232289A1 (en) 2021-04-27 2022-11-03 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
AU2023235112A1 (en) 2022-03-14 2024-10-17 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
WO1993007897A1 (en) * 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
EP0903408A3 (en) * 1992-08-21 2005-11-02 Biogen, Inc. Tat-derived transport polypeptide
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
PL322143A1 (en) * 1995-03-08 1998-01-05 Neovacs Non-topxic immunogenes originating frommretroviral regulator protein, antibodies as such, method of preparing them and pharmaceutic compositions containing them
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
ATE338128T1 (de) 2006-09-15
TR200000864T2 (tr) 2000-08-21
AU746564B2 (en) 2002-05-02
HK1030431A1 (en) 2001-05-04
ZA988789B (en) 2000-03-29
WO1999016884A1 (en) 1999-04-08
PL339432A1 (en) 2000-12-18
KR20010024287A (ko) 2001-03-26
NZ503482A (en) 2001-09-28
NO328824B1 (no) 2010-05-25
AU1025599A (en) 1999-04-23
CO4810339A1 (es) 1999-06-30
SI1015596T1 (sl) 2007-02-28
EP1015596A1 (en) 2000-07-05
CZ20001091A3 (cs) 2000-09-13
CZ302878B6 (cs) 2012-01-04
DE69835756T3 (de) 2010-09-30
JP2001518300A (ja) 2001-10-16
SA98190877B1 (ar) 2006-09-10
CN1188519C (zh) 2005-02-09
NO20001508L (no) 2000-05-18
AR017147A1 (es) 2001-08-22
PL195243B1 (pl) 2007-08-31
NO20001508D0 (no) 2000-03-23
PT1015596E (pt) 2006-12-29
CA2305013C (en) 2008-04-08
DK1015596T4 (da) 2010-07-12
BR9812547A (pt) 2000-07-25
ES2272012T3 (es) 2007-04-16
NO20076467L (no) 2000-05-18
HUP0004896A1 (hu) 2001-04-28
CN1279718A (zh) 2001-01-10
DE69835756T2 (de) 2007-09-13
EP1015596B1 (en) 2006-08-30
KR100554487B1 (ko) 2006-03-03
TW499436B (en) 2002-08-21
HUP0004896A3 (en) 2003-05-28
ES2272012T5 (es) 2010-07-06
GB9720585D0 (en) 1997-11-26
DE69835756D1 (de) 2006-10-12
IL135102A0 (en) 2001-05-20
CA2305013A1 (en) 1999-04-08
JP2009213492A (ja) 2009-09-24
EP1015596B2 (en) 2010-04-14
SI1015596T2 (sl) 2010-07-30
DK1015596T3 (da) 2007-01-02

Similar Documents

Publication Publication Date Title
AR017147A1 (es) Composicion de vacuna de proteina que comprende una proteina nef de vih, dicha proteina, metodo para prepararla y metodo para producir dicha vacuna
ES2535084T3 (es) Proteínas N-glicosiladas recombinantes procedentes de células procariotas
DE60126913D1 (de) Nucleinsäure bindende polypeptide gekennzeichnet durch flexible linker verbundene nucleinsäuredomäne
NI200800193A (es) Anticuerpos humanos anti-il-23, composiciones, métodos y usos.
PL369741A1 (en) Immunocytokines with modulated selectivity
DE10195927T1 (de) Verallgemeinerte Textlokalisation in Bildern
DK1326630T3 (da) Anvendelse af GLP-2-peptider
EP1039398A3 (en) Scheme for systematically registering meta-data with respect to various types of data
SE0100901D0 (sv) New composition
BG101103A (bg) Теломераза при бозайници
DK1364029T3 (da) Fusionsprotein, der omfatter hirudin og proinsulin eller insulin
TR27026A (tr) Erkek-kisir bitkileri, erkek-kisir bitkiler elde etmeye mahsus yöntem ve bunlarin icinde kullanima mahsus rekombinant dna.
ATE307593T1 (de) Mit einem tensid co-mikronisiertes progestin, pharmazeutische zusammensetzung dieses enthaltend,verfahren zu deren herstellung sowie verwendung
ES2571852T3 (es) Moléculas mutantes CTLA4 solubles y usos de las mismas
DE50302281D1 (de) Endoprothese mit einer Trägerstruktur aus einer Magnesiumlegierung
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
MXPA02005946A (es) Jeringa prellenada y metodo para fabricar la misma.
EA200700973A1 (ru) Слитый белок, содержащий домен bh3 белка «вh3-только»
ATE368734T1 (de) Cutinase-varianten
ATE323763T1 (de) Dna & protein bindende miniatur proteine
EP1456376A4 (en) NEW CHIMERAL REV, TAT AND NEF ANTIGENES
AR017190A1 (es) Metodo para mejorar la resistencia o tolerancia a patogenos en una planta que comprende integrar en el genoma de dicha planta un gen que codificauna proteina de fusion que comprende una primer y segunda proteina o dominio de proteina con actividad antipatogenica, molecula de adn, su uso, proteinade
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
AR027791A1 (es) Proteinas de fusion con hemolisina, produccion y uso de las mismas
IT1286829B1 (it) Plasmidi contenenti due o piu' competitori disposti in successione e loro uso in tecniche di pcr-competitiva

Legal Events

Date Code Title Description
FA Abandonment or withdrawal